Gene · 8030
Papers1,913
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,913
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Anlotinib in combination with trifluridine-tipiracil in patients with refractory metastatic colorectal cancers: a phase II, single arm study. | Oncologist | 2026 | 41719193 | PubTator, text mining | PubMed |
| Proteome-Wide Analysis of Functional Phosphosites in the FGFR Family of Proteins: Insights from Large-Scale Phosphoproteomic Analysis. | Proteomes | 2026 | 41718090 | PubTator, text mining | PubMed |
| Molecular pathogenesis and therapeutic advances in RET fusion-positive papillary thyroid carcinoma. | Pathol Res Pract | 2026 | 41713135 | PubTator, text mining | PubMed |
| RET Fusion-Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-Mutation Profiles, and Implications for Targeted and Immunotherapy. | Lung Cancer | 2026 | 41707338 | PubTator, text mining | PubMed |
| Acquired CCDC6-RET Fusion After First-Line Osimertinib in Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma: A Case Report. | Cureus | 2026 | 41694974 | PubTator, text mining | PubMed |
| Design, synthesis, and activity evaluation of RET protein degradation based on PROTAC and HyTTD techniques. | Bioorg Med Chem Lett | 2026 | 41692312 | PubTator, text mining | PubMed |
| Therapeutic Potential of Tyrosine Kinase Inhibitors in Advanced Thyroid Cancer. | Curr Oncol Rep | 2026 | 41642503 | PubTator, text mining | PubMed |
| Pharmacological perturbation of splicing elicits SMG1 reduction: Implications for cancer therapy. | iScience | 2026 | 41623476 | PubTator, text mining | PubMed |
Pre-ablation stimulated thyroglobulin to TSH ratio as a strong predictor of non-generally satisfactory response to initial radioiodine therapy in papillary thyroid carcinoma patients undergoing lateral neck dissection. | Ann Med | 2026 | 41601151 | PubTator, text mining | PubMed |
| Molecular Subtyping and Prognostic Prediction in Pancreatic Cancer Based on Mitophagy-Related Genes. | Int J Med Sci | 2026 | 41583513 | PubTator, text mining | PubMed |
| The multiple roles of the disordered protein CCDC6 in cancer development. | Int J Cancer | 2026 | 41578974 | PubTator, text mining | PubMed |
| Cytological Features of High-Grade Medullary Thyroid Carcinoma: A Comparative Study With Low-Grade Cases. | Diagn Cytopathol | 2026 | 41567073 | PubTator, text mining | PubMed |
| Actionable driver gene alterations in early-stage non-small cell lung cancer: a review. | Ther Adv Med Oncol | 2026 | 41555859 | PubTator, text mining | PubMed |
| Co-Regulation of PySLD5 by miRNA-lncRNA Enhances Cold Tolerance in Poplar Under Overwintering Freeze-Thaw Stress. | Plant Cell Environ | 2026 | 41507118 | PubTator, text mining | PubMed |
| Comparative parametric analysis of solar adsorption cooling systems driven by evacuated tube and parabolic trough concentrators in hot arid climates. | Sci Rep | 2026 | 41491202 | PubTator, text mining | PubMed |
| Pervasive phenotypic effects of FBXO42 are promoted by regulation of PP4 phosphatase. | EMBO J | 2026 | 41484364 | Swiss-Prot, curated | PubMed |
| CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC. | Cancer Res Commun | 2026 | 41417832 | PubTator, text mining | PubMed |
| A Novel, Ruxolitinib-Sensitive, CCDC6::JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera-Like, Myeloproliferative Neoplasm. | Am J Hematol | 2026 | 41335026 | PubTator, text mining | PubMed |
| Tumor-infiltrating T Lymphocytes Recognize Thyroid-specific Proteins and Neo-antigens in Follicular Cell-derived Thyroid Cancers. | J Clin Endocrinol Metab | 2026 | 41275380 | PubTator, text mining | PubMed |
| Enhanced Diagnosis of Chronic Antibody-mediated Rejection Using Peritubular Capillary Multilayering. | Transplantation | 2026 | 41063352 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8030/papers?page=3